Goldman Sachs’s CRISPR Therapeutics CRSP Stock Holding History

Goldman Sachs’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,500	Closed	-$511K	–	5688
2024 Q1	$511K	Sell	7,500 -21,600	-74%	-$1.55M	﹤0.01%	4738
2023 Q4	$1.82M	Sell	29,100 -41,900	-59%	-$2.32M	﹤0.01%	3999
2023 Q3	$3.22M	Hold	71,000	–	–	﹤0.01%	3373
2023 Q2	$3.99M	Hold	71,000	–	–	﹤0.01%	3301
2023 Q1	$3.21M	Sell	71,000 -95,700	-57%	-$4.65M	﹤0.01%	3468
2022 Q4	$6.78M	Sell	166,700 -161,800	-49%	-$8.58M	﹤0.01%	2919
2022 Q3	$21.5M	Buy	328,500 +185,000	+129%	+$13.4M	0.01%	1800
2022 Q2	$8.72M	Buy	+143,500	New	+$8.44M	﹤0.01%	2646
2021 Q2	–	Sell	-13,200	Closed	-$1.61M	–	6241
2021 Q1	$1.61M	Buy	13,200 +4,000	+43%	+$604K	﹤0.01%	4200
2020 Q4	$1.41M	Buy	+9,200	New	+$1.09M	﹤0.01%	3973
2020 Q1	–	Sell	-11,000	Closed	-$670K	–	5248
2019 Q4	$670K	Buy	+11,000	New	+$601K	﹤0.01%	4347
2018 Q4	–	Sell	-1,000	Closed	-$44K	–	5289
2018 Q3	$44K	Sell	1,000 -500	-33%	-$26.2K	﹤0.01%	5312
2018 Q2	$88K	Buy	+1,500	New	+$85.5K	﹤0.01%	5241

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs's CRSP Position: Q1 2026 in Review

Goldman Sachs increased its CRISPR Therapeutics (CRSP) stake by 50% in Q1 2026, buying an estimated $7.31M and bringing the position to 414,220 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

Goldman Sachs first reported a position in CRSP in Q4 2017 and has held it in 34 quarters since. The position peaked at $48.7M in Q3 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Goldman Sachs held 414,220 shares of CRISPR Therapeutics worth $19.7M as of Q1 2026.
Goldman Sachs bought 138,588 CRISPR Therapeutics shares in Q1 2026, an estimated $7.31M.
CRISPR Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2448 holding.
Goldman Sachs first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 34 quarters since.
Goldman Sachs's CRISPR Therapeutics position peaked at $48.7M in Q3 2022.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.